Synonym
(±)-C75; C75; C75 FASN inhibitor; trans-C75
IUPAC/Chemical Name
tetrahydro-4-methylene-2R-octyl-5-oxo-3S-furancarboxylic acid
InChi Key
CWLZDVWHQVAJU-JHJMLUEUSA-N
InChi Code
InChI=1S/C14H22O4/c1-3-4-5-6-7-8-9-11-12(13(15)16)10(2)14(17)18-11/h11-12H,2-9H2,1H3,(H,15,16)/t11-,12?/m1/s1
SMILES Code
O=C([C@@H](C1=C)[C@@H](CCCCCCCC)OC1=O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
254.33
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Tseng KY, Liu KH, Wu HM, Lin S. The fatty acid synthase inhibitor C75
differentially affects the adipogenic differentiation of multipotent cells and
preadipocytes. FEBS Lett. 2022 Dec;596(24):3191-3202. doi:
10.1002/1873-3468.14424. Epub 2022 Jun 21. PMID: 35689495.
2: Matsuo S, Yang WL, Aziz M, Kameoka S, Wang P. Fatty acid synthase inhibitor
C75 ameliorates experimental colitis. Mol Med. 2014 Jan 17;20(1):1-9. doi:
10.2119/molmed.2013.00113. PMID: 24306512; PMCID: PMC3912252.
3: Chen C, Han X, Zou X, Li Y, Yang L, Cao K, Xu J, Long J, Liu J, Feng Z.
4-methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid (C75), an inhibitor
of fatty-acid synthase, suppresses the mitochondrial fatty acid synthesis
pathway and impairs mitochondrial function. J Biol Chem. 2014 Jun
13;289(24):17184-94. doi: 10.1074/jbc.M114.550806. Epub 2014 May 1. PMID:
24784139; PMCID: PMC4059159.
4: Rae C, Fragkoulis GI, Chalmers AJ. Cytotoxicity and Radiosensitizing Activity
of the Fatty Acid Synthase Inhibitor C75 Is Enhanced by Blocking Fatty Acid
Uptake in Prostate Cancer Cells. Adv Radiat Oncol. 2020 Jun 29;5(5):994-1005.
doi: 10.1016/j.adro.2020.06.022. PMID: 33083663; PMCID: PMC7557210.
5: Lupu R, Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase
(FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer
agents? Curr Pharm Biotechnol. 2006 Dec;7(6):483-93. doi:
10.2174/138920106779116928. PMID: 17168665.
6: Relat J, Blancafort A, Oliveras G, Cufí S, Haro D, Marrero PF, Puig T.
Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and
C75 in adenocarcinoma lung cancer. BMC Cancer. 2012 Jul 6;12:280. doi:
10.1186/1471-2407-12-280. PMID: 22769244; PMCID: PMC3500220.
7: Wise JTF, Kondo K. Increased Lipogenesis Is Important for Hexavalent
Chromium-Transformed Lung Cells and Xenograft Tumor Growth. Int J Mol Sci. 2023
Dec 2;24(23):17060. doi: 10.3390/ijms242317060. PMID: 38069382; PMCID:
PMC10707372.
